<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>ADHDMedications.com: label update log</title>
  <link href="https://adhdmedications.com/label-updates.html"/>
  <link rel="self" href="https://adhdmedications.com/label-updates.xml"/>
  <id>https://adhdmedications.com/label-updates.xml</id>
  <updated>2026-10-30T12:00:00Z</updated>
  <author><name>ADHDMedications.com</name></author>
  <entry>
    <title>Simtriyo (centanafadine) placed in DEA Schedule III; now marketable</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-30-simtriyo"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-30-simtriyo</id>
    <updated>2026-10-30T12:00:00Z</updated>
    <summary>Oct 30, 2026: The DEA published an interim final rule placing centanafadine in Schedule III (CIII), effective the same day: 91 FR 68470, FR Doc. 2026-22208, Docket No. DEA-1743. Public comments are due Nov 30, 2026. FDA approval of Simtriyo became effective when the rule was published, so Simtriyo can now be marketed. The Prescribing Information revised 10/2026 is labeled CIII. DailyMed (SPL version 1, published Oct 26, 2026) lists a marketing start date of Oct 24, 2026. No Otsuka launch press release was found and pharmacy stocking was not confirmed as of Nov 4, 2026: check pharmacy availability. There is no generic or authorized generic.</summary>
  </entry>
  <entry>
    <title>Ritalin LA (brand): marketing end dates listed on DailyMed</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-29-ritalin-la"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-29-ritalin-la</id>
    <updated>2026-10-29T12:00:00Z</updated>
    <summary>Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision): DailyMed’s listing for brand Ritalin LA (Novartis; SPL version 36) shows marketing end dates of Sep 30, 2026 for the 10 mg and 30 mg capsules and Oct 31, 2026 for the 20 mg and 40 mg capsules. These are marketing dates in the product listing, not a change to the label, which is still revised 9/2025. The Sandoz authorized-generic listing shows its capsules as marketed with no end date. The FDA Orange Book still lists the 10 to 40 mg brand strengths as active (rechecked Oct 29, 2026).</summary>
  </entry>
  <entry>
    <title>Mylan generic methylphenidate patch: marketing end dates listed on DailyMed</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-29-daytrana"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-29-daytrana</id>
    <updated>2026-10-29T12:00:00Z</updated>
    <summary>Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision): DailyMed’s listing for Mylan’s generic methylphenidate transdermal system (SPL version 6) shows marketing end dates of Jan 31, 2027 for the 30 mg patch and Apr 30, 2027 for the 10, 15 and 20 mg patches. These are marketing dates in the product listing, not a change to the label. As of Oct 29, 2026, ASHP lists Mylan (Viatris) patches as available, and the Padagis authorized-generic listing shows no end date.</summary>
  </entry>
  <entry>
    <title>Aptensio XR: marketing end date listed on DailyMed; listing dropped from DailyMed search</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-29-aptensio-xr"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-29-aptensio-xr</id>
    <updated>2026-10-29T12:00:00Z</updated>
    <summary>Oct 29, 2026 (DailyMed listing checked; marketing end dates, not a label revision): DailyMed’s listing for brand Aptensio XR (Rhodes; SPL version 17, published May 25, 2026) shows a marketing end date of May 20, 2026 for all seven strengths. This is a marketing date in the product listing, not a change to the label. On Oct 29, 2026 the listing no longer appeared in DailyMed search results, although its page still opened from a direct link. The FDA Orange Book still lists all seven strengths as active, and ASHP lists the brand and the Rhodes authorized generic on back order.</summary>
  </entry>
  <entry>
    <title>Simtriyo label posted on DailyMed (before DEA scheduling)</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-26-simtriyo"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-26-simtriyo</id>
    <updated>2026-10-26T12:00:00Z</updated>
    <summary>Oct 26, 2026: DailyMed posted the Simtriyo (centanafadine) label; that version stated that the controlled-substance schedule was pending (the label revised 10/2026 is labeled CIII). The DEA rule to place centanafadine in Schedule III finished federal (OIRA) review on Oct 22, 2026; it was published on Oct 30, 2026 (see that entry), which made the FDA approval effective.</summary>
  </entry>
  <entry>
    <title>Metadate CD label revised (Lannett)</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-10-21-metadate-cd"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-10-21-metadate-cd</id>
    <updated>2026-10-21T12:00:00Z</updated>
    <summary>Oct 2026 (label revised 10/2026; DailyMed SPL date Oct 21, 2026): Indication is now pediatric patients 6 years and older (previously ages 6 to 15); the label is not indicated for adults. Alcohol is now listed as a drug interaction (section 7); the Medication Guide’s most common side effects add headache and stomach pain; contraindications are listed in full (Recent Major Changes: Contraindications, 07/2026).</summary>
  </entry>
  <entry>
    <title>Simtriyo (centanafadine) approved by FDA</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-07-24-simtriyo"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-07-24-simtriyo</id>
    <updated>2026-07-24T12:00:00Z</updated>
    <summary>Jul 24, 2026: FDA approved Simtriyo (NDA 218145, Otsuka) for ADHD in adults and in children 6 and older who weigh at least 20 kg; label dated 07/2026. Marketing had to wait for DEA scheduling, which took effect Oct 30, 2026 (see that entry).</summary>
  </entry>
  <entry>
    <title>Strattera label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-06-30-strattera"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-06-30-strattera</id>
    <updated>2026-06-30T12:00:00Z</updated>
    <summary>Jun 2026 (label revised 6/2026; DailyMed SPL date Jun 30, 2026): The label was revised 6/2026 but lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Concerta label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-04-20-concerta"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-04-20-concerta</id>
    <updated>2026-04-20T12:00:00Z</updated>
    <summary>Apr 2026 (label revised 4/2026; DailyMed SPL date Apr 20, 2026): Dosage sections 2.3 (patients new to methylphenidate) and 2.4 (patients switching from another methylphenidate product) changed in 2/2026. The warnings on seizures and on periodic hematologic (blood count) monitoring were removed in 2/2026. Also listed as recent: the 9/2025 Indications change (not recommended under age 6) and the long-term growth suppression warning.</summary>
  </entry>
  <entry>
    <title>Vyvanse label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-04-vyvanse"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-04-vyvanse</id>
    <updated>2026-04-01T12:00:00Z</updated>
    <summary>April 2026: Current label revised 4/2026 (DailyMed SPL date April 30, 2026). Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.</summary>
  </entry>
  <entry>
    <title>QuilliChew ER label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-04-quillichew-er"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-04-quillichew-er</id>
    <updated>2026-04-01T12:00:00Z</updated>
    <summary>April 2026: Current label revised 4/2026 (DailyMed SPL date April 8, 2026). Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025; Dosage Forms and Strengths (3), 03/2026.</summary>
  </entry>
  <entry>
    <title>Mydayis label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-04-mydayis"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-04-mydayis</id>
    <updated>2026-04-01T12:00:00Z</updated>
    <summary>April 2026: Current label revised 4/2026 (DailyMed SPL date April 30, 2026). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Adderall XR label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-04-adderall-xr"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-04-adderall-xr</id>
    <updated>2026-04-01T12:00:00Z</updated>
    <summary>April 2026: Current label revised 4/2026 (DailyMed SPL date April 30, 2026). Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.</summary>
  </entry>
  <entry>
    <title>Atoncy (atomoxetine oral solution) approved; marketing started</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-03-20-atoncy"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-03-20-atoncy</id>
    <updated>2026-03-20T12:00:00Z</updated>
    <summary>Mar 20, 2026: FDA approved Atoncy, a 4 mg/mL atomoxetine oral solution (NDA 220320), on Mar 20, 2026; DailyMed lists Atoncy and an authorized generic with a marketing start of Mar 20, 2026. Current label revised 3/2026 (first DailyMed version effective Apr 2, 2026).</summary>
  </entry>
  <entry>
    <title>Arynta marketing started</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-03-20-arynta"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-03-20-arynta</id>
    <updated>2026-03-20T12:00:00Z</updated>
    <summary>Mar 20, 2026: DailyMed lists a marketing start date of Mar 20, 2026 for Arynta (approved Jun 16, 2025, NDA 219847).</summary>
  </entry>
  <entry>
    <title>Quillivant XR label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2026-03-quillivant-xr"/>
    <id>tag:adhdmedications.com,2026:label-updates/2026-03-quillivant-xr</id>
    <updated>2026-03-01T12:00:00Z</updated>
    <summary>March 2026: Current label revised 3/2026 (DailyMed SPL date March 24, 2026). Recent Major Changes listed on the label: Dosage Forms and Strengths (3), 03/2026; Indications and Usage (1), 09/2025; Warnings and Precautions (5.7 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.</summary>
  </entry>
  <entry>
    <title>DEA and HHS extend telemedicine prescribing of controlled medicines through 2026</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-12-31-stimulant-labels"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-12-31-stimulant-labels</id>
    <updated>2025-12-31T12:00:00Z</updated>
    <summary>Dec 31, 2025: The DEA, jointly with HHS, published a fourth temporary extension of the COVID-19 telemedicine flexibilities for prescribing controlled medications (90 FR 61301, FR Doc. 2025-24123). It is effective Jan 1, 2026 through Dec 31, 2026. The flexibilities let practitioners prescribe Schedule II–V controlled medications, which include ADHD stimulants, through audio-video telemedicine visits without the in-person evaluation the Ryan Haight Act otherwise requires, provided the prescriptions meet the other requirements. No further extension had been published in the Federal Register as of Nov 9, 2026.</summary>
  </entry>
  <entry>
    <title>Arynta label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-12-arynta"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-12-arynta</id>
    <updated>2025-12-01T12:00:00Z</updated>
    <summary>December 2025: Current label revised 12/2025 (DailyMed SPL date July 30, 2025). DailyMed’s SPL effective date is earlier than the revision date printed on the label; both are shown as published. Recent Major Changes listed on the label: Indications and Usage (1), 09/2025; Warnings and Precautions (5.5 Long-Term Suppression of Growth in Pediatric Patients), 09/2025.</summary>
  </entry>
  <entry>
    <title>Methylphenidate ER (10/20 mg) label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-10-methylphenidate-er-tablets"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-10-methylphenidate-er-tablets</id>
    <updated>2025-10-01T12:00:00Z</updated>
    <summary>October 2025: Current label revised 10/2025 (DailyMed SPL date October 8, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Kapvay label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-10-kapvay"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-10-kapvay</id>
    <updated>2025-10-01T12:00:00Z</updated>
    <summary>October 2025: Current label revised 10/2025 (DailyMed SPL date October 31, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Stimulant labels: use under age 6 not recommended; growth warning revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-09-30-stimulant-labels"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-09-30-stimulant-labels</id>
    <updated>2025-09-30T12:00:00Z</updated>
    <summary>Sep 2025: These labels list two Recent Major Changes dated 09/2025: Indications and Usage (section 1) now states that use is not recommended in children younger than 6 because they had higher drug exposure and more side effects (such as weight loss) at the same dose, and the Long-Term Suppression of Growth in Pediatric Patients warning was revised.</summary>
  </entry>
  <entry>
    <title>Intuniv label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-06-intuniv"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-06-intuniv</id>
    <updated>2025-06-01T12:00:00Z</updated>
    <summary>June 2025: Current label revised 6/2025 (DailyMed SPL date June 23, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Evekeo label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-06-evekeo"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-06-evekeo</id>
    <updated>2025-06-01T12:00:00Z</updated>
    <summary>June 2025: Current label revised 06/2025 (DailyMed SPL date October 10, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Zenzedi label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-05-zenzedi"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-05-zenzedi</id>
    <updated>2025-05-01T12:00:00Z</updated>
    <summary>May 2025: Current label revised 05/2025 (DailyMed SPL date November 26, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>ProCentra label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-05-procentra"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-05-procentra</id>
    <updated>2025-05-01T12:00:00Z</updated>
    <summary>May 2025: Current label revised 05/2025 (DailyMed SPL date May 14, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Onyda XR label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-04-onyda-xr"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-04-onyda-xr</id>
    <updated>2025-04-01T12:00:00Z</updated>
    <summary>April 2025: Current label revised 4/2025 (DailyMed SPL date April 11, 2025). Recent Major Changes listed on the label: Warnings and Precautions (5.3 Rebound Hypertension), 04/2025.</summary>
  </entry>
  <entry>
    <title>Methylphenidate Chewable label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-03-methylphenidate-chewable-tablets"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-03-methylphenidate-chewable-tablets</id>
    <updated>2025-03-01T12:00:00Z</updated>
    <summary>March 2025: Current label revised 3/2025 (DailyMed SPL date March 12, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Ritalin label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-02-ritalin"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-02-ritalin</id>
    <updated>2025-02-01T12:00:00Z</updated>
    <summary>February 2025: Current label revised 2/2025 (DailyMed SPL date February 5, 2025). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Qelbree label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2025-01-qelbree"/>
    <id>tag:adhdmedications.com,2026:label-updates/2025-01-qelbree</id>
    <updated>2025-01-01T12:00:00Z</updated>
    <summary>January 2025: Current label revised 1/2025 (DailyMed SPL date October 5, 2026). The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
  <entry>
    <title>Desoxyn label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2024-09-desoxyn"/>
    <id>tag:adhdmedications.com,2026:label-updates/2024-09-desoxyn</id>
    <updated>2024-09-01T12:00:00Z</updated>
    <summary>September 2024: Current label revised 9/2024 (DailyMed SPL date September 30, 2024). Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.9 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.</summary>
  </entry>
  <entry>
    <title>Focalin label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2024-05-focalin"/>
    <id>tag:adhdmedications.com,2026:label-updates/2024-05-focalin</id>
    <updated>2024-05-01T12:00:00Z</updated>
    <summary>May 2024: Current label revised 5/2024 (DailyMed SPL date May 30, 2024). Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 Recommended Dosage), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.</summary>
  </entry>
  <entry>
    <title>Methylin label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2023-11-methylin"/>
    <id>tag:adhdmedications.com,2026:label-updates/2023-11-methylin</id>
    <updated>2023-11-01T12:00:00Z</updated>
    <summary>November 2023: Current label revised 11/2023 (DailyMed SPL date November 1, 2023). Recent Major Changes listed on the label: Boxed Warning, 10/2023; Dosage and Administration (2.1 Pretreatment Screening; 2.2 General Dosing Information; 2.3 Dosage Reduction and Discontinuation), 10/2023; Warnings and Precautions (5.1 Abuse, Misuse, and Addiction; 5.2 Risks to Patients with Serious Cardiac Disease; 5.8 Acute Angle Closure Glaucoma; 5.9 Increased Intraocular Pressure and Glaucoma; 5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome), 10/2023.</summary>
  </entry>
  <entry>
    <title>Adhansia XR label revised</title>
    <link href="https://adhdmedications.com/label-updates.html#entry-2021-06-adhansia-xr"/>
    <id>tag:adhdmedications.com,2026:label-updates/2021-06-adhansia-xr</id>
    <updated>2021-06-01T12:00:00Z</updated>
    <summary>June 2021: Current label revised 6/2021. The label lists no Recent Major Changes, so the specific edits were not identified for this log.</summary>
  </entry>
</feed>
